Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyper-NC is a topical ophthalmic solution containing hypertonic sodium chloride, developed and marketed by Grevis Pharma. It is primarily indicated for the temporary relief of corneal edema and the reduction of epithelial swelling. The drug operates through a physical osmotic mechanism rather than binding to a specific molecular receptor. By increasing the tonicity of the tear film, it creates an osmotic gradient that draws excess fluid out of the edematous corneal epithelium and stroma. This reduction in swelling helps improve visual clarity and alleviate discomfort associated with conditions such as Fuchs' endothelial dystrophy or post-surgical corneal edema.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hyper-NC.